Choosing between good options .

This chapter is drawn from Part 2 of the book, which addresses the decision framework for men with localised prostate cancer. It is offered here as a representative example of the book’s approach: evidence-grounded, values-conscious, and written for the man in the room rather than for the clinician beside him.

The surgeon told me about the possible complications. Incontinence, erectile dysfunction — mentioned, explained, documented. With nerve sparing, he said, the erectile function would likely resolve itself. I heard the words. What I did not hear, in any meaningful sense, was what they would mean in the daily life of the man I was about to become.

I saw the physiotherapist twice before the surgery — she explained the procedure, the catheter management, the penile health protocol, what my body would need from me in the weeks that followed. She told me more about the practical reality of what I had agreed to than the surgeon had. But the consent was already signed. The date was already in the diary. The most practically grounded account of what this treatment would cost me arrived after the decision, even though it arrived before the surgery.

I was lucky. I was 60, physically strong, and the surgery left me, after the initial adjustment, without lasting functional impact. I learned new rules for a body that had changed, and I adapted. Many men do not adapt as cleanly. Many men who receive the same nerve-sparing surgery, the same reassurances, and the same post-operative physiotherapy find themselves living with consequences that the word “complications” did not adequately prepare them for.

I am not saying my outcome was wrong. I am saying that a good outcome is not the same thing as a well-made decision.

Luck is not a strategy, and it is not a standard against which a decision-making process should be measured. This chapter is for the man who wants to make a genuine choice — not a fear-driven one, not one carried by clinical habit, but one grounded in honest understanding of what each option offers, what each option costs, and which costs he can genuinely live with.

Why the evidence doesn’t resolve the choice

For men with low-risk and carefully selected intermediate-risk prostate cancer, the outcome data for surgery, radiation, and active surveillance are remarkably similar over ten and fifteen-year horizons. The ProtecT trial, which randomised over 1,600 men with localised prostate cancer to radical prostatectomy, radiotherapy, or active monitoring, found no significant difference in prostate cancer-specific mortality between the three groups at fifteen years. The cancer-specific survival rate across all three arms exceeded 97 percent.

If surgery, radiation, and surveillance produce equivalent cancer-specific survival, what is the basis for choosing between them? The answer is that the treatments are not equivalent in what they cost.

That finding is both reassuring and, for the man trying to choose between treatment options, initially bewildering. The ProtecT trial found that the three groups diverged significantly on urinary, bowel, and sexual function — and that those differences were not trivial and did not fully resolve over time.

The choice between good options is therefore not primarily a statistical exercise. It is a values exercise.

The evidence narrows the field to a set of options with comparable oncological outcomes. The question then is which option’s costs and benefits are most aligned with this man’s priorities, his tolerance for different kinds of functional disruption, and his relationship to the specific uncertainty that each option carries. Medicine cannot make that determination. It can inform it. Only the man can make it.

What each option actually costs

The side effects of prostate cancer treatment are discussed in clinical consultations, documented in consent forms, and described in patient information materials. They are also, in my experience, not fully heard in the pre-treatment period — because the cancer is too loud in the room for the complications to register at their actual weight.

Surgery removes the prostate and, with it, the source of PSA. A post-surgical PSA that reaches an undetectable nadir provides a clarity that radiation cannot offer — the primary tumour site is gone, and a rising PSA after that nadir is an unambiguous signal. That clarity is real and it is something many men value. What surgery also does is cut the urethral sphincter from its anatomical context, disrupt the neurovascular bundles that supply erectile function, and create a body that must relearn continence from new neurological ground. The literature on long-term urinary and sexual function after radical prostatectomy shows a wide distribution of outcomes, and the men at the adverse end of that distribution are living a reality that the median outcome figure does not represent.

Radiation treats the cancer in place and avoids the surgical disruption of the sphincter mechanism and neurovascular architecture. The functional consequences emerge differently and over a longer timeline — bowel irritation, urinary frequency and urgency, and erectile function that may decline gradually over years as radiation effect accumulates in surrounding tissue. For men who most want to avoid the acute functional disruption of surgery and who can tolerate a monitoring picture that is inherently more complex to interpret, radiation may be the more appropriate choice.

Active surveillance avoids both surgical and radiation consequences in the immediate term and preserves all treatment options for the future. What it requires is the ability to live with a known, monitored cancer without immediate treatment, for a period that may extend to years or decades, through repeated PSA tests, periodic MRI scans, and interval biopsies. For men who understand the natural history data and can hold that understanding calmly through the cycle of monitoring, surveillance is not merely tolerable — it is the most biologically rational approach for selected disease states. For men who find the knowledge of an untreated cancer psychologically corrosive regardless of what the evidence says about its behaviour, surveillance will not serve them well regardless of how appropriate it is clinically. That is not a failure of intelligence or courage. It is self-knowledge, and self-knowledge is a legitimate clinical input.

The physiotherapist problem

The physiotherapist who saw me before my surgery knew things that my surgeon did not tell me. Not because the surgeon lacked the knowledge — he was technically accomplished and the surgery was well-performed. But because the physiotherapist’s expertise lay in exactly the territory that the surgical consultation does not naturally cover: what happens to a man’s body after the procedure, how he learns to manage a sphincter that now operates on different neurological terms, what the rehabilitation actually requires.

She arrived before the surgery but after the decision. The information she carried — the most grounded, most practically relevant account of what this treatment would do to my daily life — arrived in the window between commitment and procedure, when her role was preparation rather than deliberation. Pre-surgery is not the same as pre-decision. She came too late to influence the choice, even though she came before the knife.

This is not unique to surgery. Radiation oncology has equivalent expertise in its nursing and allied health teams about the bowel and urinary consequences of pelvic radiation that rarely reaches patients in the pre-treatment consultation. Active surveillance programmes have specialist nurses who understand the psychological demands of monitored cancer in ways that the urologist who recommends surveillance may not articulate. In every treatment pathway, the deepest practical knowledge lives in the allied health professionals who see the post-treatment reality — and it reaches patients too late.

Before you consent to any treatment, ask to speak with the physiotherapist, the specialist nurse, or the allied health professional who works with men after that treatment. Ask them what the first three months actually look like.

Ask what the range of outcomes is, not just the median. Ask what men most wish they had known before they started.

What you actually value

I valued certainty. In 2019, with the word cancer in the room and no framework for understanding what my specific disease was likely to do, certainty felt like the only rational goal. Remove it. Know it is gone. Settle into whatever normal follows. That was the value that drove my decision — and it was never explicitly named, never evaluated, never placed alongside the alternative values that a different framework might have surfaced.

Certainty is a legitimate value. So is functional preservation. So is the avoidance of treatment-related side effects that persist for years. So is the psychological relief of not living with monitored untreated cancer. So is the preservation of therapeutic options for the future. These values are not always compatible with each other, and the trade-offs between them are not resolvable by evidence alone. The evidence tells you what each option is likely to produce. Your values tell you which production you are willing to pay for.

What makes a choice genuine is not the outcome it produces. It is the process by which it is made.

Whether the man understood what he was choosing between, whether his values were made explicit rather than assumed, and whether the decision reflected his priorities rather than the priorities embedded in the clinical pathway he happened to enter. I did not fully understand the choice I was making in 2019. I made a fear-driven one in which my values were assumed rather than surfaced, and the outcome happened to serve me well. That is not the same as wisdom.

Studies following men after treatment find that most do not regret the treatment they chose — they regret not understanding their options at the time of the decision. That form of regret is entirely preventable. It is what this chapter is designed to prevent.

The future biology of each choice

There is one dimension of the choice between good options that the ProtecT trial and most clinical discussions do not address directly: what each option does to the future biology of the disease and to the therapeutic options that remain available if the disease progresses.

Surgery removes the prostate and forecloses further local treatment to that site. If PSA rises after surgery, the options are salvage radiation to the prostatic bed and systemic therapy. Radiation introduces tissue changes — fibrosis, vascular changes, altered anatomy — that make salvage surgery technically difficult and functionally risky. Active surveillance preserves all local treatment options, because no treatment has yet been delivered.

These are not arguments for any particular choice. They are arguments for understanding what each choice does to the landscape that follows it. A man with low-risk disease who is 55 years old has a very long potential disease course ahead of him. The choice he makes now will shape the options available to him if his disease evolves over the next twenty years.

The goal is not to choose the option that optimises any single dimension. It is to choose the option whose combination of immediate costs, long-term functional consequences, psychological demands, and future biological implications is most aligned with the man’s values, his tolerance for uncertainty, and the life he intends to keep living.

That choice belongs to him. It always did.

Questions to clarify what you value before choosing

The evidence can tell you what each treatment is likely to achieve and what it is likely to cost. It cannot tell you which costs are acceptable to you. These questions are designed to surface the values that the evidence alone cannot resolve.

A clinician can help you understand what each option offers and what it costs. Only you can determine which costs are worth bearing and which offerings matter. That determination is not a burden the doctor should carry. It is the decision that belongs to you.